Testosterone, beyond libido

What testosterone actually does across your body

Testosterone gets introduced as a libido medication. The libido improvement is real — but it's one piece of a broader picture most women are never told about. Testosterone receptors exist in tissues throughout your body, and replacing what you've lost has effects you'll feel beyond sex.

The Menopause Clinic4 minute readUpdated for current TMC patients

Below is the view across your body. Every system on this page is one where research has shown testosterone plays a real role in women — and where the decline shows up in ways most women are never taught to connect to a hormone. The in-depth libido guide at the bottom cites the specific studies, and is the longer read if you want depth on libido specifically.

Two things to know going in. Testosterone starts declining in your 30s — long before perimenopause itself — which is why the changes often feel like aging or stress rather than something hormonal. And no woman experiences these effects evenly across every system. The pattern is real, the magnitude varies, and what's most prominent for you may not match what's most prominent for someone else.

01

Brain

  • Thinking gets clearer — focus holds, words come faster, the gap between thought and speech closes
  • Memory works better, especially the small things that had started slipping
  • The brain fog lifts
  • Sleep is deeper and more restorative
  • Motivation and drive come back — caring about things, wanting things, having opinions again
  • The mental noise quiets — fewer "what's wrong with me" loops in the background
Testosterone receptors live throughout the brain. The cognitive shift is one of the most underrecognized parts of replacement — and often the first thing women notice.
02

Energy & mood

  • Energy settles into a more stable baseline — not a caffeine spike, just having enough fuel for your day
  • Mood steadies; fewer days where everything feels like too much
  • The flat, low-motivation quality that had crept in — the one that started to feel like personality — lifts
  • A sense of vitality returns. Confidence with it.
The energy and mood shifts usually arrive earlier than the sexual changes. They're often the first signal the medication is working.
03

Muscle

  • Strength returns — picking things up, carrying groceries, the small physical capacity that had quietly faded
  • Lean body mass increases, body fat tends to decrease — especially with strength training in the mix
  • The anabolic response improves: your body's capacity to build and hold muscle comes back
Women don't need male-range doses to see this. The best evidence comes from RCTs comparing estrogen + testosterone to estrogen alone, with consistent gains in strength and lean mass.
04

Bones

  • Bone density holds — and in some women, increases — through and after menopause
  • Fracture risk drops, especially at the hip, wrist, and spine — the fractures that change lives
  • Works alongside estrogen, not as a substitute; together the protective effect is stronger than either alone
One of the slower effects to show up — and one of the most consequential for long-term health. Most of what we know comes from observational and genetic studies in women; the dedicated fracture-endpoint trials are still being run.
05

Libido

  • Desire becomes available again — not necessarily out-of-nowhere wanting, but the capacity to want, to respond, to be interested
  • Arousal is easier; once something starts, the body responds the way it used to
  • Orgasm becomes more reliable, often easier to reach
  • Genital sensitivity returns; the dulled, flat quality lifts
  • Urinary urgency and small leaks ease as the tissue heals
The full sexual response usually takes 3–12 months to deepen. The in-depth libido guide covers the realistic timeline.
06

Heart

  • Triglycerides — one of the cardiovascular risk markers that climbs after menopause — tend to come down
  • HDL cholesterol tends to rise; the overall lipid balance shifts in a less atherogenic direction
  • Blood vessels work better — flow-mediated dilation improves at physiologic doses
  • Blood pressure stays stable; glucose handling is unaffected on transdermal replacement
Most of what's known here is about risk markers, not cardiac events. The 2019 Global Consensus found no harm at physiological doses — but the large trials with hard cardiac endpoints needed to claim protection haven't been done.
07

Eyes

  • The dryness, grittiness, and burning that started in perimenopause begins to resolve
  • Tears come in the right consistency again — eyes stop feeling raw by afternoon
  • Screens and reading are more comfortable
Dry eye is one of the most rarely-attributed signs of low testosterone in perimenopause. The meibomian glands are an androgen target organ — and dry eye is more strongly linked to low androgens than to low estrogen. Specific treatment trials for systemic replacement remain limited.
08

Bladder

  • The pelvic floor, urethra, and bladder tissues — all androgen-responsive — get the support they depend on
  • Stress and mixed incontinence become less frequent; women with higher testosterone have meaningfully lower rates of both
  • The urgency — the can't-quite-make-it-to-the-bathroom feeling — eases as the tissue rebuilds
The bladder, urethra, and pelvic floor are androgen-responsive tissues. The changes many women assume are "just aging" are often hormonally driven — and replacement helps the tissue support return. For vaginal atrophy specifically, vaginal estrogen remains the first-line treatment.
09

Side effects

  • At the physiologic female-range doses we use, side effects are uncommon — replacement keeps testosterone within the levels your body would have produced anyway
  • Acne, oilier skin, coarse facial hair, voice changes, clitoral changes — when these appear, it means blood levels have run too high. They're a signal of dose excess, not testosterone itself.
  • Between 6 and 8 weeks we recheck your labs to verify your level is in the female range, and adjust the dose if it isn't
  • If you notice anything before then, message us — we'll review your labs and dose. Individual response to adjustments varies.
Side effects, when they appear, are a calibration signal — not a verdict on the medication. The 2019 Global Consensus found adverse events at physiologic dosing in trials to be uncommon.
Where to go from here

The breadth, in context

That's the view across your body. If you want depth on any one system, the guides below are where to go next. The in-depth libido guide is the longest read — it covers the realistic timeline, what testosterone won't fix, and how to tell whether it's working for you.

Testosterone: the in-depth guide
The reframe, the timeline, how to tell if it's working
→
What to expect, week by week
Personalized timeline after a dose change
→
Starting testosterone
Requirements and steps before your first prescription
→
Continuing testosterone
Labs, visits, and refill requirements over time
→

Everything on this page comes from research on testosterone in women. The studies grounding each system are listed below.

Key research

The sources behind this page

These are the specific studies that ground each system. For the deeper libido research — particularly dose-response data and individual variation — the in-depth libido guide is the source of truth.

Foundational

  • Davis SR, Baber R, Panay N, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women. Journal of Clinical Endocrinology & Metabolism. 2019.
  • Davis SR, Wåhlin-Jacobsen S. Testosterone in women — the clinical significance. The Lancet Diabetes & Endocrinology. 2015.

Brain, Energy & mood

  • Glynne S, Kamal A, Kamel AM, Reisel D, Newson L. Effect of transdermal testosterone therapy on mood and cognitive symptoms in peri- and postmenopausal women: a pilot study. Archives of Women's Mental Health. 2024;28(3):541–550.
  • Glynne S, Kamal A, McColl L, et al. Transdermal oestradiol and testosterone therapy for menopausal depression and mood symptoms: retrospective cohort study. British Journal of Psychiatry. Published online June 16, 2025.

Muscle & body composition

  • Covered by the Davis & Wåhlin-Jacobsen 2015 review (above), which summarizes the RCT evidence on estrogen + testosterone vs. estrogen alone for lean body mass and strength.

Bones

  • Davis SR, McCloud P, Strauss BJ, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas. 1995.
  • Lee JS, LaCroix AZ, Wu L, et al. Associations of serum sex hormone-binding globulin and sex hormone concentrations with hip fracture risk in postmenopausal women. Journal of Clinical Endocrinology & Metabolism. 2008.
  • Cauley JA, Danielson ME, Jammy GR, et al. Sex steroid hormones and fracture in a multiethnic cohort of women: the Women's Health Initiative. Journal of Clinical Endocrinology & Metabolism. 2017.
  • Quester J, Nethander M, Coward E, et al. High SHBG and low bioavailable testosterone are strongly causally associated with increased forearm fracture risk in women: a Mendelian randomization study. Calcified Tissue International. 2024.

Heart & vascular

  • Islam RM, Bell RJ, Handelsman DJ, et al. Associations between blood sex steroid concentrations and risk of major adverse cardiovascular events in healthy older women in Australia: a prospective cohort substudy of the ASPREE trial. The Lancet Healthy Longevity. 2022.
  • Davis SR, Azene ZN, Tonkin AM, et al. Higher testosterone is associated with higher HDL-cholesterol and lower triglyceride concentrations in older women. Climacteric. 2024.
  • Davis SR. Testosterone and the heart: friend or foe? Climacteric. 2024.
  • Iellamo F, Volterrani M, Caminiti G, et al. Testosterone therapy in women with chronic heart failure: a pilot double-blind, randomized, placebo-controlled study. Journal of the American College of Cardiology. 2010.

Eyes & dry eye

  • Sullivan DA, Sullivan BD, Evans JE, et al. Androgen deficiency, meibomian gland dysfunction, and evaporative dry eye. Annals of the New York Academy of Sciences. 2002.
  • Clayton JA. Dry eye. New England Journal of Medicine. 2018.
  • Sriprasert I, Warren DW, Mircheff AK, Stanczyk FZ. Dry eye in postmenopausal women: a hormonal disorder. Menopause. 2016.

Bladder & urogenital tissue

  • Simon JA, Goldstein I, Kim NN, et al. The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) Expert Consensus Panel Review. Menopause. 2018.
  • Kim MM, Kreydin EI. The association of serum testosterone levels and urinary incontinence in women. Journal of Urology. 2018.
  • Bell RJ, Rizvi F, Islam RM, Davis SR. A systematic review of intravaginal testosterone for the treatment of vulvovaginal atrophy. Menopause. 2018.

Individual response varies. Nothing on this page substitutes for clinical care — if anything you're noticing differs from what you expected, message us.